Home > Oncology > ASCO 2019 > Developmental Therapeutics - Immunotherapy > IL-6 and C-reactive protein as potential biomarkers for checkpoint inhibition

IL-6 and C-reactive protein as potential biomarkers for checkpoint inhibition

Presented By
Dr Jeffrey S. Weber, Laura and Isaac Perlmutter Cancer Centre, USA
Conference
ASCO 2019
Trial
CheckMate-064, CheckMate-066, CheckMate-067
Medical writer: Muriel Cunningham Elevations of C-reactive protein (CRP) and interleukin-6 (IL-6) are associated with poor outcomes in cancers such as melanoma, lung, colorectal, and breast. CRP is synthesized in the liver in response to different stimuli, including IL-6. To further explore the associations between IL-6, CRP, and patient outcomes, an investigation was conducted using samples from patients with melanoma enrolled in three studies of checkpoint inhibitors. Jeffrey S. Weber, MD, PhD, of the Laura and Isaac Perlmutter Cancer Centre, NYU Langone Medical Centre, presented the results of this study (Abstract 100). Pretreatment and on-treatment serum samples from patients with melanoma enrolled in the following three studies were analysed: CheckMate-064 (140 patients; NCT01783938), CheckMate-066 (418 patients; NCT01721772), and CheckMate-067 (945 patients; NCT01844505). Levels of CRP and IL-6 were measured using Luminex multiplex panels. Analyses of...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on